I85PREP
⌘ K
ANCC PMHNP study materials
ANCC PMHNP study resources

The Adolescent Who Won't Take Her Meds

ANCC PMHNP · Put your knowledge to work in context.

All case studies

The Adolescent Who Won't Take Her Meds

Sofia, 15, was hospitalized three weeks ago after a suicide attempt (overdose of her mother's sertraline) and was discharged on fluoxetine 20 mg daily with a diagnosis of major depressive disorder and a plan for weekly therapy. At today's visit she is flat, answers in monosyllables, and her mother reports she has not been taking the fluoxetine for at least 10 days. Sofia says, "It doesn't help and it makes me feel weird." She denies current suicidal ideation but says "sometimes I think everyone would be better off." She refuses to discuss the medication further and asks you not to tell her mother. Her mother is in the waiting room and has legal custody.

1. Sofia asks you not to tell her mother about her nonadherence and passive suicidal statements. How do you handle confidentiality?

Read the worked answer

This is a safety-based disclosure, not a routine confidentiality breach.

  • Assess first: passive SI ("better off") in a 15-year-old with a recent attempt and current nonadherence is a meaningful risk signal. Complete a structured risk assessment (ideation, plan, intent, means, protective factors, collateral).
  • Legal/ethical frame: Minors generally lack full confidentiality; parents/guardians with custody are entitled to information necessary for care, and the duty to protect overrides the teen's request when risk is present. State this to Sofia transparently before disclosure - "I can keep most things private, but if I'm worried about your safety I have to involve your mom."
  • Disclose narrowly: Share what is necessary for safety (nonadherence, passive SI, safety plan), not the full content of her session.
  • Engage Sofia: Offer to have the conversation together, give her a voice in how it's framed, and document her assent/dissent and your reasoning.
  • Escalate if needed: If risk is imminent, arrange emergency evaluation regardless of parental preference.

2. What are the differential considerations for her nonresponse and nonadherence, and what do you do about the medication?

Read the worked answer

"Makes me feel weird" plus nonresponse warrants a broad differential:

  • Adverse effects: activation, akathisia, GI upset, emotional blunting - common in adolescents on SSRIs. Ask specifically about each.
  • Dosing/timing: 20 mg may be subtherapeutic or poorly tolerated; consider timing and food.
  • Wrong diagnosis: bipolar disorder (screen for hypomania/mania - activation on an SSRI can be a clue), PTSD, substance use, psychotic process.
  • Psychosocial: family conflict, bullying, school stress, sleep disruption.
  • Medical: thyroid, anemia.

Plan:

  1. Do not simply re-prescribe. Explore the "weird" feeling in detail.
  2. If activation/akathisia → reduce dose or switch agent (e.g., escitalopram, sertraline) with close monitoring.
  3. If blunting → discuss dose reduction or switch.
  4. Screen for bipolarity before continuing an antidepressant; if positive, reassess the plan.
  5. Combine with evidence-based psychotherapy (CBT, DBT-A, IPT-A) - medication alone is inadequate here.
  6. Consider a higher level of care (IOP) given recent attempt and current passive SI.

3. What does the evidence say about antidepressant safety in adolescents, and how do you counsel the family?

Read the worked answer

Key evidence points to convey accurately:

  • Black-box warning (2004): increased risk of suicidality (ideation/behavior, not completed suicide) in patients <25, especially early in treatment and after dose changes. Absolute risk is small but real; benefit still generally outweighs risk for moderate-severe MDD.
  • Monitoring: FDA recommends weekly in-person or phone contact for the first 4 weeks, then biweekly for 4 weeks, then at 12 weeks and as clinically indicated.
  • Efficacy: Fluoxetine and escitalopram have the strongest evidence in adolescents; psychotherapy plus medication outperforms either alone.

Counseling script:

  • Explain the warning plainly, without frightening them away from treatment.
  • Teach warning signs: new or worsening SI, agitation, akathisia, insomnia, irritability, unusual energy - call immediately.
  • Provide a written safety plan and crisis numbers; ensure means restriction (lock up medications, including the mother's sertraline).
  • Emphasize that stopping abruptly is not the answer and that we will adjust rather than abandon treatment.
  • Schedule the next visit within one week and document the safety discussion.